Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Prostate cancer hormone therapy may cloud thinking in seniors

NCT ID NCT00579072

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether hormone therapy (like Lupron or Casodex) changes thinking abilities in men aged 65 and older with prostate cancer. Researchers will compare cognitive function over time between men starting hormone therapy, those who have never had it, and those who have been on it for months to years. The goal is to understand potential side effects on memory and thinking, not to treat the cancer itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

230 people

The number who actually took part.

Start date

Aug 2006

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Prostate Cancer Patients

Ages

65 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria is the same at both sites, and is outlined below: Inclusion Criteria: Comparison Androgen Ablation Group 1. Diagnosis of prostate cancer 2. Age 65 or older 3. Ability to converse, write and read English 4. In the investigator's judgment, participants must have satisfactory cognitive function to provide valid informed consent and participate in the neurocognitive testing. The Blessed Orientation-Memory-Concentration test (BOMC) will be used as a cognitive screening tool. Patients must have a BOMC score of less than or equal to 11. 5. Able to provide informed consent 6. Have been on continuous androgen ablation therapy for 6 months to-3 years Longitudinal Androgen Ablation Subgroup 1. Diagnosis of prostate cancer 2. Age 65 or older 3. Ability to converse, write and read English 4. Able to provide informed consent 5. In the investigator's judgment, participants must have satisfactory cognitive function to provide valid informed consent and participate in the neurocognitive testing. The Blessed Orientation-Memory-Concentration test (BOMC) will be used as a cognitive screening tool. Patients must have a BOMC score of less than or equal to 11. 6. Starting androgen ablation therapy or started within the past 21 days 7. No androgen ablation therapy within the past year No Androgen Ablation Subgroup 1. Diagnosis of prostate cancer 2. Age 65 or older 3. In the investigator's judgment, participants must have satisfactory cognitive function to provide valid informed consent and participate in the neurocognitive testing. The Blessed Orientation-Memory-Concentration test (BOMC) will be used as a cognitive screening tool. Patients must have a BOMC score of less than or equal to 11. 4. At least 1-year post definitive localized treatment 5. Ability to converse, write and read English 6. Able to provide informed consent 7. Not anticipated to start androgen ablation therapy 8. No history of androgen ablation therapy Exclusion Criteria: All Groups 1. Previous or current treatment with chemotherapy 2. As per medical record or self-report, a history of central nervous system stroke, history of traumatic brain injury, or diagnosis of neurogenerative disorder that affects cognitive function (e.g. Alzheimer's, Parkinson's, Multiple Sclerosis, dementia, seizure disorders, etc.) 3. History of untreated psychiatric disease 4. As per medical record or self-report, history of loss of consciousness for 60+ minutes and/or admitted to the hospital for a head injury 5. Current use of opioids 6. History of developmental disorders 7. Current or history of alcohol or substance abuse 8. Visual, auditory, or other impairment that would preclude ability to complete neuropsychological testing (e.g. significant macular degeneration, being unable to correct hearing with hearing aides, hand tremors, etc.) CRITERIA FOR OPTIONAL fMRI Exclusion Criteria: * Patient has a self-reported fear of enclosed spaces (Claustrophobia) * As per self report or as identified in the medical record, patient has any of the following items that preclude fMRI evaluation: * Cardiac pacemaker * Joint replacements * Aneurysm clips * Transdermal patched * Aortic clips * Prosthesis * Intracranial bypass clips * Harrington rod * Coronary Artery bypass clips * Biostimulator * Renal Transplant Clips * Bone or joint pins * Other vascular clips or filters * Tissue expander * Implanted neurostimulators * Metal mesh * Artificial heart valve * Stents * Insulin pump * Wire structures * Electrodes * Shrapnel/bullets * Hearing Aids /implant * Implanted electrical devices * IUD Metal in eyes * Shunts * Ocular Implants * Hair extensions * Hair implants * Tattoos above the waist * Any possible metal in body * As per self report, patient has dentures, body jewelry or wig that they are unable to remove

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope

    Duarte, California, 91010, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.